Prostate Cell News Volume 4.29 | Aug 2 2013

Scaffold Attachment Factor B1 Regulates the Androgen Receptor in Concert with the Growth Inhibitory Kinase MST1 and the Methyltransferase EZH2
Investigators report that the nuclear matrix protein, scaffold attachment factor B1, regulates androgen receptor (AR) activity and AR levels in a manner that suggests its involvement in prostate cancer. [Oncogene] Abstract

The Significance of Galectin-3 as a New Basal Cell Marker in Prostate Cancer
Scientists found that in various prostate cancer cell lines galectin-3 expression was always opposite to androgen receptor expression and other luminal cell markers but consistent with basal cell markers including glutathione S-transferase-p and Bcl-2. [Cell Death Dis] Full Article

Synthesis and In Vitro and In Vivo Evaluation of Hypoxia-Enhanced ¹¹¹In-Bombesin Conjugates for Prostate Cancer Imaging
Researchers demonstrated that incorporation of one or more 2-nitroimidazoles into the gastrin-releasing peptide receptor-targeted peptide significantly increases the in vitro retention of the agent in hypoxic prostate cancer cells. [J Nucl Med] Abstract

Proteasome Inhibition by Bortezomib Increases IL-8 Expression in Androgen-Independent Prostate Cancer Cells: The Role of IKKa
Scientists report that proteasome inhibition by bortezomib unexpectedly increases IL-8 expression in androgen-independent prostate cancer PC3 and DU145 cells, whereas expression of other NF-?B-regulated genes is inhibited or unchanged. [J Immunol] Abstract

PTEN Loss Mediated Akt Activation Promotes Prostate Tumor Growth and Metastasis via CXCL12/CXCR4 Signaling
Loss of phosphatase and tensin homolog (PTEN) resulted in increased expression of CXCR4 and CXCL12 and Akt inhibition reversed expression and cellular invasion. These results suggest that loss of PTEN may play a key role in the regulation of this chemokine activity in prostate cancer. [Mol Cancer]
Abstract | Full Article

Retigeric Acid B-Induced Mitophagy by Oxidative Stress Attenuates Cell Death against Prostate Cancer Cells In Vitro
In both PC3 and LNCaP cells, retigeric acid B increased ROS accumulation and decreased mitochondrial transmembrane potential in a time-dependent manner. [Acta Pharmacol Sin] Abstract

Modulation of the Response of Prostate Cancer Cell Lines to Cisplatin Treatment Using Small Interfering RNA
Researchers showed that cisplatin treatment increased JNK-1 and JNK-2 activity and expression in both LNCaP and PC-3 cells. [Oncol Rep] Abstract

Effects of the Monoamine Oxidase Inhibitors Pargyline and Tranylcypromine on Cellular Proliferation in Human Prostate Cancer Cells
The authors investigated the effects of the monoamine oxidase inhibitors, pargyline and tranylcypromine on cell survival in human prostate carcinoma cells. The proliferation of cells exposed to pargyline decreased in a dose- and time-dependent manner, while tranylcypromine-treated cells showed the opposite results. [Oncol Rep] Abstract

CLINICAL RESEARCH

Empiric Antibiotics for an Elevated Prostate-Specific Antigen (PSA) Level: A Randomized, Prospective, Controlled Multi-Institutional Trial
The authors determined the impact of empiric antibiotics on men with an elevated PSA level. Prostate cancer was detected in 36 (47%) men, 23 (59%) in the control group and 13 (34%) in the antibiotic group. [BJU Int] Abstract

Nuclear MTA1 Overexpression Is Associated with Aggressive Prostate Cancer, Recurrence and Metastasis in African Americans
Researchers found that nuclear metastasis-associated protein 1 (MTA1) overexpression was positively correlated with the severity of disease progression reaching its highest levels in metastatic prostate cancer. Nuclear MTA1 overexpression was significantly associated with Gleason > 7 tumors in African Americans but not in Caucasians. [Sci Rep] Full Article

Visit our REVIEWS page to see a complete list of reviews in the prostate cell research field.

Stem Cell Agency’s Board Approves $70 Million Plan to Develop Innovative Alpha Clinics
A $70 million plan to create a new statewide network of sites that will act as a hub for stem cell clinical trials was approved by the governing Board of California’s stem cell agency, the California Institute for Regenerative Medicine. The goal of the Alpha Stem Cell Clinics Network is to support and accelerate clinical trials for programs funded by the agency, as well as those developed elsewhere by academic researchers, clinicians and pharmaceutical companies. [California Institute for Regenerative Medicine] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

NEW Tenure-Track Position – Cell Biologist (McGill University)

Postdoctoral Fellow – Steroid Receptor Signaling (Baylor College of Medicine)

Faculty Position – Detection and Diagnosis of Solid Tumors (Stanford University)

Lead Research Technologist – Translational Prostate Cancer Research Program (Cleveland Clinic)

Project Scientist – Prostate Cancer Research (University of California at Los Angeles)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.